《Table 2Recent clinical trials of HMP.》
提示:宽带有限、当前游客访问压缩模式
本系列图表出处文件名:随高清版一同展现
《Machine perfusion for liver transplantation: A concise review of clinical trials》
KPS:UW gluconate solution.Lifeport liver transporter,ECOPS device and Liver Assist are all commercial MP systems.Lifeport liver transporter:Organ Recovery Systems,Itasca,IL,USA;ECOPS device:Organ Assist BV,Groningen,The Netherlands;Liver Assist:Organ
In addition,the HOPE-DBD multicenter trial(NCT01317342,main end-points:postoperative peak ALT,hospital and ICU stay,patient and graft survival),DHOPE-DCD multicenter trial(NCT02584283,main end-points:biliary complications,patient and graft survival,hospital and ICU stay,PNF)and HOPE-ECD multicenter trial(NCT03124641,main end-points:postoperative peakALT,postoperative complications,hospital and ICU stay,patient and graft survival)are ongoing.These trials are expected to provide more details on the potential advantages of HMP and liver viability assessment.The details of HMP are summarized in Table 2.
图表编号 | XD0020452500 严禁用于非法目的 |
---|---|
绘制时间 | 2018.10.15 |
作者 | Jun-Juna Jia、Jian-Hui Li、Hao Yu、Yu Nie、Li Jiang、Hao-Yu Li、Lin Zhou、Shu-Sen Zheng |
绘制单位 | Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine、Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health、Collaborative Innovation Centers for Diagnosis Treatment |
更多格式 | 高清、无水印(增值服务) |